Thursday 16 October, 2025
Objectives: M7824 is an innovative first-in-class bifunctional fusion protein composed of a human IgG1 monoclonal antibody against programmed death-ligand 1 (PD-L1)…
Read morePoster: Drug/Disease Modelling - Oncology
Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers
Thursday 16 October, 2025
Introduction/Objectives: Cosibelimab is a high-affinity, fully human monoclonal antibody (mAb) of immunoglobulin G1 subtype that directly binds to PD-L1. PD-L1 is…
Read morePopulation Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats
Thursday 16 October, 2025
Introduction and Objective: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is part of a multidisciplinary treatment proposed for patients suffering from peritoneal carcinomatosis….
Read moreValidation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC
Thursday 16 October, 2025
Objectives: The xenograft mouse model is widely used to study the response to cancer therapy. Pharmacokinetic-pharmacodynamic (PKPD) modelling of xenograft…
Read moreHerceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels.
Thursday 16 October, 2025
Objectives: Previous exposure response analyses of Herceptin treatment in patients (pts) with HER2+ metastatic gastric/GEJ Cancer (TOGA study), suggested an association…
Read morePopulation pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity
Thursday 16 October, 2025
Objectives: The pharmacokinetics of the polyethylene glycol (PEG)-conjugated asparaginase Oncaspar® is characterized by an increase in elimination over time. An…
Read morePopulation Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL
Thursday 16 October, 2025
Objectives: The pharmacokinetics of the polyethylene glycol (PEG)-conjugated asparaginase Oncaspar® is characterized by an increase in elimination over time. The…
Read moreComparison of two-stage and joint TGI-OS modelling using data from six clinical studies in metastatic non-small cell lung cancer patients
Thursday 16 October, 2025
Introduction: Tumor growth inhibition (TGI)-overall survival (OS) models have been shown to predict OS distributions and study outcomes (OS hazard…
Read moreA modelling platform for onco-immunological drugs in early drug development
Thursday 16 October, 2025
Objectives: Humanised mouse models are widely used for preclinical evaluation of immuno-oncological (IO) drugs [1]. However, tumour response from these…
Read moreA disease model for Multiple Myeloma developed using Real World Data
Thursday 16 October, 2025
Objectives: Multiple myeloma (MM) is a neoplasm characterized by the proliferation and accumulation of malignant plasma cells. End-organ damage resulting…
Read more